Vas Narasimhan
Novartis CEO on $12B Avidity Deal: ‘Could Have Been Twice as Big’
Novartis; Avidity Biosciences; Vas Narasimhan; merger; acquisition; biotech; RNA therapeutics; $12 billion deal; neuromuscular diseases; SpinCo; financial outlook; growth strategy